About CamStent
CamStent Ltd is an emerging medical materials company based in Cambridge, UK. We are focused on building revenues through the development and licensing of proprietary polymer coatings that resist attachment of biofilms..
CamStent’s first commercial product is a compound that prevents catheter-acquired urinary tract infections. Derivative formulations will target other medical and dental applications, as well as consumer and marine products.
Company History
CamStent was founded in 2006 when a clinician looking for solution for stent thrombosis met a surface chemist with an interest in non-stick coatings at a Cambridge university lecture. Their collaboration became a company developing biofilm-resistant coatings for medical, consumer, and marine applications.
Awards and Investment
-
CamStent has been awarded successive grants to conduct market analyses and early stage research, including:
- £10,000 in seed funding from Cambridge University Entrepreneurs (CUE) and the Research Council (UK)
- £20,000 from the East of England Development Agency (EEDA) for market assessment of urology and cardiology applications of its polymer technology.
- £100,000 as a research grant from EEDA to conduct microbiological and materials research leading towards its first commercial product.
-
CamStent has secured £350K ($570K) first-round investment from 16 UK-based angels to bring its lead catheter product towards market, including:
- Six investors from the Yorkshire Association of Business Angels.
- Investment from the London Business Angels and Wren Capital.
We are also pleased to add investors Paul White (Barts and the London Trust) and Richard Milne (Petrofac) as non-executive directors.
Development process
Camstent follows medical device industry best practices, guided by ISO and national regulatory guidelines and standards.
The first product is currently in late-research phase, funded by an EEDA research grant and early stage investors. Validation tasks will take one year to complete, and include tailoring the coating to bond with catheter substrates and demonstrating effective resistance against relevant microorganisms.
With a successful demonstration of the component feasibiility, the product will rapidly be brought to commercial readiness in the subsequent 24 months during which optimization, CE Mark approval and a short clinical study will take place.
-
10.12.2009
CamStent launches website
Read more...As part of our commitment to quality, we updated our website so we can give better information about our company and the projects we're working on. Let us know what you think.
- About CamStent
- Technology
- Meet the team
